文献速递艾滋病与性传播感染

初始抗逆转录病毒治疗方案中整合酶抑制剂、非核苷逆转录酶抑制剂或增强蛋白酶抑制剂对免疫恢复的影响

Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该回顾性研究纳入836例初始ART的HIV感染者,比较以InSTI、NNRTI或bPI为第三药物的方案在病毒抑制后2年内CD4+计数、CD4+百分比及CD4+/CD8+比值的恢复情况。结果显示,三种方案在CD4+和CD4+百分比恢复上无显著差异;bPI组CD4+/CD8+比值增幅略高于InSTI组,但临床意义可忽略。结论认为免疫恢复与第三药物类别无关。

要点

  • 以InSTI、NNRTI或bPI为第三药物的初始ART方案,CD4+和CD4+百分比恢复无差异。
  • bPI组CD4+/CD8+比值增幅略高于InSTI组,但差异临床意义可忽略。
  • 免疫恢复程度与第三种抗逆转录病毒药物类别无关。

核心结论

  • 以CD4+计数、CD4+百分比和CD4+/CD8+比值增幅衡量的免疫恢复,与初始ART方案中第三药物类别无关。

研究设计与样本

  • 回顾性分析纳入836例初始ART的HIV感染者,分别使用InSTI(208例)、NNRTI(481例)或bPI(147例)联合两种NRTIs。
  • 要求维持同一第三药物且病毒载量达标后HIV-RNA<50 copies/mL的检测比例≥95%。
  • 采用混合效应回归模型分析2年内CD4+计数、CD4+百分比和CD4+/CD8+比值的变化。

主要发现

  • CD4+和CD4+百分比在0-6个月和6-24个月两个阶段的斜率变化,按第三药物类别比较均无显著差异(第一阶段P=0.137和P=0.393;6个月后P=0.834和P=0.159)。
  • bPI组CD4+/CD8+比值增幅略高于InSTI组(差值0.0119,95%CI 0.0020-0.0205;P=0.018),但临床意义可忽略;6个月后组间无差异(P=0.176)。
  • InSTI组患者达到病毒载量检测不到的速度更快。

临床怎么用

  • 初始ART方案选择时,免疫恢复不应作为区分InSTI、NNRTI或bPI方案的依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse whether integrase inhibitor (InSTI)-based regimens achieve better immunological recovery than NNRTI- or boosted PI (bPI)-based regimens as initial ART. METHODS: In a retrospective analysis, we selected patients who initiated ART with two NRTIs plus an InSTI, an NNRTI or a bPI and maintained both the same 'third drug' and an HIV-RNA <50 copies/mL in ≥95% of determinations once undetectable viral load had been achieved. We compared CD4+ count, %CD4+ and CD4+/CD8+ ratio recovery over 2 years. Data were analysed using mixed-effects regression models for repeated measures. RESULTS: Of the 836 patients included, 208, 481 and 147 initiated with InSTI, NNRTI and bPI, respectively. For CD4+, %CD4+ and CD4+/CD8+ two main slopes were identified: from month 0 to month 6, with the highest increments; and from month 6 to month 24, with smaller increases every semester. Although the patients on InSTI achieved undetectable viral load faster, for CD4+ and %CD4+ there were no differences in the slopes of change according to the third drug either for the first phase (P=0.137 and P=0.393, respectively) or from month 6 onwards (P=0.834 and P=0.159, respectively). The increase in CD4+/CD8+ was slightly higher for bPI compared with InSTI (difference of 0.0119, 95% CI 0.0020-0.0205; P=0.018), but clinically negligible. From month 6 onwards, no differences were found between treatment groups (P=0.176). CONCLUSIONS: Immune restoration measured as CD4+ count, %CD4+ and CD4+/CD8+ increases was independent of the third antiretroviral drug class used when given with two NRTIs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Milanés-Guisado Y, Gutiérrez-Valencia A, Muñoz-Pichardo JM, et al. Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients? J Antimicrob Chemother. 2020. PMID: 31617904. doi:10.1093/jac/dkz421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。